The CST group is responsible for the analysis and due diligence required for all business development activities and acts as the Company’s point of contact for capital providers, investment banks and analysts. The CST group is also responsible for building the financial model framework the Company will use to assess current and future performance.
Peter joins Radius from
Kelly Martin commented that, “Peter is an outstanding individual and professional. His broad and deep experience will provide Radius with a better understanding of our current business as well as valuable objective assessments of future opportunities or adjustments.”
Peter earned his B.A. from
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics.
For more information, please visit www.radiuspharm.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
These forward-looking statements are based on management's current expectations. These statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: the Company’s expectations in connection with the creation of the CST group and its new members, and the Company’s expectations regarding business development activities and financial modeling. These and other important risks and uncertainties discussed in our filings with the
Investor Relations Contact:
Source: Radius Health Inc.